Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Misses Estimates By $0.59 EPS

Capricor Therapeutics (NASDAQ:CAPR) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.59), FiscalAI reports.

Capricor Therapeutics Stock Performance

CAPR stock traded down $0.98 during trading on Tuesday, reaching $8.87. 4,428,802 shares of the company traded hands, compared to its average volume of 3,162,323. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The business has a 50 day simple moving average of $8.09 and a 200 day simple moving average of $20.13. The company has a market capitalization of $515.70 million, a price-to-earnings ratio of -3.62 and a beta of 0.80.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CAPR. Maxim Group cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. LADENBURG THALM/SH SH cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Piper Sandler upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Finally, Cantor Fitzgerald upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $30.25.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.